EpimAb Biotherapeutics and Vignette Bio Partner to Develop EMB-06 for Autoimmune Disorders
Shots:
- EpimAb Biotherapeutics has signed a license agreement with Vignette Bio for the development of EMB-06 in autoimmune disorders
- EpimAb will keep the exclusive development & commercialization rights of EMB-06 in Greater China (Mainland China, Hong Kong, Macau, Taiwan) and will get $60M upfront (cash & equity), $575M development, regulatory & commercial milestones along with net-sales-based royalties. Vignette secures rights outside of Greater China
- EMB-06 is a BCMA×CD3 bispecific Ab developed using EpimAb's platform that integrates FIT-Ig bispecific platform and CD3 binder panel. The platform enables rapid discovery and screening of TCE candidates for advancing them into clinical studies
Ref: EpimAb | Image: EpimAb
Related News:- EpimAb Biotherapeutics Entered into a License Agreement with Almirall to Develop Bispecific Antibody
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
